high Ab group	placebo	Prolonged abstinence from smoking rates to 6 months	-1	-1	3�??AmNic-rEPA recipients in the high Ab group were significantly more likely to attain 8 weeks of continuous abstinence from weeks 19 through 26 than placebo (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14�??6.37).
low Ab group	placebo	Prolonged abstinence from smoking rates to 12 months	-1	-1	As a secondary outcome, continuous abstinence rate (CAR) to 52 weeks were evaluated from weeks 19 to 52 and were significantly higher for the high Ab group vs. placebo (19.7% vs. 10.0%, p=0.044, OR=2.64, 95% CI, 1.03�??6.79) with no significant difference between the low Ab group and placebo
non-abstainers (weeks 19–52) with high Ab levels	non-abstainers in the placebo group	Reduction of daily cigarette consumption and cotinine	8389	8651	Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19–52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C
low Ab group	placebo	Prolonged abstinence from smoking rates to 6 months	7812	8061	>Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53–12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).
recipients with the highest serum anti-nicotine antibody response (top 30% by AUC)	placebo group	attain 8 weeks continuous abstinence from weeks 19 through 26	-1	-1	3�??AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14�??6.37).
low Ab group	placebo	Prolonged abstinence from smoking rates to 12 months	8062	8312	Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32–11.20). The low Ab group did not differ significantly from placebo (7.1% vs. 6.0%, p=0.67).
non-abstainers (weeks 19–52) with high Ab levels	non-abstainers in the placebo group	Reduction of daily cigarette consumption and cotinine	8388	8652	>Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19–52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C.
low Ab group	placebo	Prolonged abstinence from smoking rates to 6 months	-1	-1	Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53�??12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).
recipients with the highest serum anti-nicotine antibody response (top 30% by AUC)	placebo group	attain 8 weeks continuous abstinence from weeks 19 through 26	-1	-1	3?AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14?6.37).
high Ab group	placebo	Prolonged abstinence from smoking rates to 6 months	7812	8061	>Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53–12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).
high Ab group	placebo	Prolonged abstinence from smoking rates to 12 months	8062	8228	Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32–11.20).
high Ab group	placebo	Prolonged abstinence from smoking rates to 12 months	8062	8227	Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32–11.20)
recipients with the highest serum anti-nicotine antibody response (top 30% by AUC)	placebo group	attain 8 weeks continuous abstinence from weeks 19 through 26	575	850	3'AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37).
high Ab group	placebo	Prolonged abstinence from smoking rates to 12 months	-1	-1	3�??AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14�??6.37).
high Ab group	placebo	Prolonged abstinence from smoking rates to 6 months	7813	7966	Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53–12.71)
low Ab group	placebo	Prolonged abstinence from smoking rates to 6 months	7968	8061	ith no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).
